

1 BRIAN M. BOYNTON  
Acting Assistant Attorney General  
2 GUSTAV W. EYLER  
Director  
3 Consumer Protection Branch  
4 NATALIE N. SANDERS  
ROGER J. GURAL  
5 Trial Attorneys  
Consumer Protection Branch  
6 U.S. Department of Justice  
7 450 5th Street, NW, Suite 6400-South  
Washington, D.C. 20530  
8 Telephone: (202) 307-0174  
Facsimile: (202) 514-8742  
9 E-mail: Roger.Gural@usdoj.gov  
Attorneys for Plaintiff  
10 UNITED STATES OF AMERICA  
11

12 UNITED STATES DISTRICT COURT  
13 FOR THE CENTRAL DISTRICT OF CALIFORNIA  
14 EASTERN DIVISION

15 UNITED STATES OF AMERICA,

16 Plaintiff,

17 v.

18 CALIFORNIA STEM CELL  
19 TREATMENT CENTER, INC.,  
20 *et al.*

21 Defendants.  
22  
23  
24  
25  
26  
27  
28

No. 5:18-CV-01005-JGB-KKx

**PLAINTIFF'S RESPONSE TO  
DEFENDANTS' NOTICE OF RECENT  
DECISION**

Trial: May 4 – 13, 2021

Honorable Jesus G. Bernal  
United States District Judge

**PLAINTIFF’S RESPONSE TO DEFENDANTS’ NOTICE OF RECENT  
DECISION**

Plaintiff United States of America respectfully submits this response to the Notice of Recent Decision filed by Defendants in connection with *United States v. California Stem Cell Treatment Center, Inc.* ECF No. 175. In their Notice of Recent Decision, Defendants submitted for this Court’s consideration a D.C. Circuit opinion in *The Judge Rotenberg Educ. Ctr., Inc. v. United States Food & Drug Admin.*, Case No. 20-1087, -- F.4th -- 2021 WL 2799891, at \*1 (D.C. Cir. July 6, 2021). Contrary to Defendants’ representation, *Rotenberg* does not address any legal issues currently pending before this Court.

In *Rotenberg*,<sup>1</sup> a divided D.C. Circuit panel held that under section 516 of the Federal Food, Drug, and Cosmetic Act (“FDCA”), 21 U.S.C. § 360f, FDA may not ban a medical device for a particular use while allowing that device to continue to be lawfully marketed and distributed for different intended uses. The *Rotenberg* majority held that a ban based on a device’s particular use would impermissibly regulate healthcare practitioners’ ability to prescribe the device for that use, and would conflict with a different section of the FDCA that codified the practice of prescribing medical devices for off-label use, 21 U.S.C. § 396 (“Nothing in this Act shall . . . limit or interfere with the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient...”). *See Rotenberg*, 2021 WL 2799891, at \*1.

The instant case, however, does not pertain to FDA’s authority to ban a medical device under 21 U.S.C. § 360f. Nor are all devices used by Defendants to manufacture their stromal vascular fraction drug products legally marketed devices. Indeed, one of the primary devices Defendants use in the manufacturing process – namely, the Time Machine device – has not been cleared or approved by FDA. *See* Plaintiff’s Revised

---

<sup>1</sup> The time for seeking further review of the panel’s opinion in *Rotenberg* has not yet run.

[Proposed] Findings of Fact and Conclusions of Law, ECF No. 169-1 ¶¶ 190-195 (providing citations to trial evidence establishing that Time Machine is not now and never has been cleared or approved by FDA). Further, none of Defendants' three drugs and biological products at issue in this case is approved by FDA for any use. For the same reasons set forth in Plaintiff's Revised [Proposed] Findings of Fact and Conclusions of Law, Defendants' practice of medicine defense fails. *See* ECF 169-1 ¶¶ 86-87.

Dated: August 6, 2021

Respectfully Submitted,

BRIAN M. BOYNTON  
Acting Assistant Attorney General

GUSTAV W. EYLER  
Director  
Consumer Protection Branch

/s/ Roger J. Gural  
NATALIE N. SANDERS  
ROGER J. GURAL  
Consumer Protection Branch  
U.S. Department of Justice  
450 5th Street, NW, Suite 6400-South  
Washington, D.C. 20530  
Telephone: (202) 307-0174  
Facsimile: (202) 514-8742  
E-mail: Roger.Gural@usdoj.gov

*Counsel for United States of America*

Of Counsel:

DANIEL J. BERRY  
Acting General Counsel  
Department of Health and Human  
Services

1 PERHAM GORJI  
2 Deputy Chief Counsel for Litigation

3 MICHAEL SHANE  
4 MICHAEL HELBING  
5 Associate Chief Counsel for Enforcement  
6 United States Food and Drug  
7 Administration  
8 Office of the Chief Counsel  
9 White Oak 31, Room 4554  
10 10903 New Hampshire Avenue  
11 Silver Spring, MD 20993-0002  
12 Telephone: 301-796-8593

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**CERTIFICATE OF SERVICE**

I hereby certify that on this 6th day of August 2021, I electronically filed a true and correct copy of the foregoing PLAINTIFF'S RESPONSE TO DEFENDANTS' NOTICE OF RECENT DECISION through the Court's CM/ECF system, which will send a notice of electronic filing to the following counsel of record listed below:

Celeste M. Brecht  
Ramanda R. Luper  
JONES DAY

Matthew M. Gurvitz  
Thomasina E. Poirot  
Nicole N. King  
Witt W. Chang  
VENABLE LLP

/s/ Roger J. Gural  
ROGER J. GURAL